Country: Malta
Language: English
Source: Medicines Authority
BEZAFIBRATE
Hennig Arzneimittel GmbH & Co KG Liebigstrasse 1-2, D-65439 Flörsheim am Main, Germany
C10AB02
BEZAFIBRATE 400 mg
FILM-COATED TABLET
BEZAFIBRATE 400 mg
POM
LIPID MODIFYING AGENTS
Withdrawn
2006-11-01
IMPORTANT INFORMATION - PLEASE READ CAREFULLY! BEFIBRAT ® 400 MG RETARD Sustained release tablets COMPOSITION: Each film-coated tablet contains: Active ingredient: 400 mg bezafibrate Excipients: lactose, poly(ethylacrylate, me- thylmethacrylate), polysorbate 80, magne- sium stearate, talcum, titanium dioxide (E 171), macrogol, maize starch, poly(O- carboxymethyl)starch-sodium salt, hypro- mellose HENNIG ARZNEIMITTEL GMBH & CO KG 65439 FLÖRSHEIM GERMANY INDICATIONS: Disturbances of lipid metabolism which cannot sufficiently be influenced neither by dietary therapy nor by other measures such as increased physical exercise and weight loss; disturbances of lipid metabolism con- ditioned by existing diseases (e.g. diabe- tes) and which persist despite of treatment of such diseases. CONTRA-INDICATIONS: Impaired renal function (serum creatinine > 1,5 mg/dl, creatinine clearance < 60ml/ min), severe hepatic dysfunctions, biliary affection with or without cholelithiasis, known hypersensitivity to any of the compo- nents of the drug, known hypersensitivity of the skin to light (photo-allergic or phototoxic reactions) after intake of drugs of the fibrate group. Pregnancy and lactation period. In children, therapy with bezafibrate should carefully be considered. PRECAUTIONS AND WARNINGS: Before instituting therapy with bezafibrate, every attempt should be made to control se- rum lipids with appropriate diet, exercise, reduction of weight and adequate treatment of a possibly existing other metabolic dys- function. In case of concomitant treatment with anti- coagulants and antidiabetics, the pro- thrombin time and blood glucose levels should be controlled regularly. The conco- mitant intake of oral contraceptives may lead to an increase of plasma triglycerides. This medicinal product contains lactose. Patients with an intolerance to some sugars must contact their doctor before taking this medical product. INTERACTIONS: BEFIBRAT ® 400 MG RETARD should not be combined with certain other lipid lowering drugs (HMG-CoA-reduc Read the complete document
Page 1 of 10 SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT Befibrat ® 400 mg retard film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Befibrat ® 400 retard film-coated tablets 1 film-coated tablet contains 400 mg bezafibrate For the list of excipients, see paragraph 6.1. 3. PHARMACEUTICAL FORM Befibrat ® 400 mg retard film-coated tablets Film-coated tablets 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Primary hyperlipoproteinaemia: - familial hypercholesterolaemia - familial hypertriglyceridaemia - familial combined hyperlipidaemia - type III hyperlipidaemia (ApoE2 homozygosis) inadequately controlled by a change in diet or other measures, such as weight reduction or increased physical activity. Secondary hyperlipoproteinaemia: - severe secondary hypertriglyceridaemia, not controllable despite consistent treatment of the underlying illness (e.g. diabetes mellitus) Dietary measures instituted prior to treatment with bezafibrate should be continued throughout treatment. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Befibrat ® 400 mg retard film-coated tablets: 1 film-coated tablet to be taken once daily (morning or evening). Note: Patients with renal insufficiency (serum creatinine values > 1.5 mg/dl or creatinine clearance < 60 ml/min) must not use Befibrat ® 400 mg retard film-coated tablets. Page 2 of 10 The coated tablets must not be chewed and must be taken with sufficient water either at mealtimes or after meals. _Dosage table _ SERUM CREATININE CREATININE CLEARANCE BEFIBRAT ® 400 MG RETARD TABLETS up to 1.5 mg/dl up to 135 µmol/l over 60 ml/min 1 film-coated tablet/day 1.6 - 2.5 mg/dl 136 - 225 µmol/l 60 - 40 ml/min contraindicated 2.6 - 6 m Read the complete document